NCT01148108View on ClinicalTrials.gov

Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Mantle Cell LymphomaB Cell LymphomaMultiple Myeloma
Interventions
DRUG

Canfosfamide HCl for injection

30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks

Trial Locations (1)

08901

Cancer Institute of New Jersey, New Brunswick

Sponsors

Lead Sponsor

Telik
All Listed Sponsors
lead

Telik

INDUSTRY